학술논문
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Document Type
Article
Author
Source
In: Diabetes, Obesity and Metabolism . (Diabetes, Obesity and Metabolism, 1 July 2020, 22(7):1151-1156)
Subject
Language
English
ISSN
14631326
14628902
14628902